AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Citigroup upgrades Bio-Techne to Buy with a new PT of $70.
ByAinvest
Thursday, Aug 21, 2025 8:48 am ET1min read
Citigroup upgrades Bio-Techne to Buy with a new PT of $70.
Citigroup has recently upgraded its recommendation for Bio-Techne Corporation (NASDAQ: TECH) to "Buy" and raised the price target to $70. This move comes amidst a series of analyst upgrades and institutional investments in the biotechnology company.The upgrade follows a significant increase in Citigroup's stake in Bio-Techne. According to its latest Form 13F filing with the Securities and Exchange Commission, Citigroup boosted its position by 131.1% during the first quarter, acquiring an additional 171,863 shares to total 302,927 shares [2].
Bio-Techne's recent earnings report also demonstrated strong performance. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate by $0.03. Revenue for the quarter was $316.96 million, up 3.6% year-over-year. The company's return on equity was 13.43%, and its net margin was 6.02% [2].
In addition to Citigroup's upgrade, several other analysts have also shown optimism towards Bio-Techne. UBS Group, Stephens, and TD Cowen have all set "buy" ratings with varying price targets, while Royal Bank of Canada has set a "sector perform" rating. Despite these positive ratings, Bio-Techne currently has an average rating of "Moderate Buy" and an average price target of $69.42 [2].
The company's stock has seen a steady increase in recent months, trading up $0.35 during midday trading on Monday, July 2, 2025, to hit $53.95. The stock's fifty-day moving average is $52.72, and its 200-day moving average is $55.17 [2].
Bio-Techne's strong financial performance and positive analyst ratings suggest that the company is well-positioned for future growth. The recent upgrades and increased institutional investment could further drive the stock's performance.
References:
[1] https://www.marketscreener.com/news/analyst-recommendations-coreweave-coty-marvell-snap-amda--ce7c51d3dc8bf327
[2] https://www.marketbeat.com/instant-alerts/filing-citigroup-inc-buys-171863-shares-of-bio-techne-corp-nasdaqtech-2025-08-14/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet